Accord Healthcare receives positive CHMP opinion for IMULDOSA®, a ustekinumab biosimilar to Stelara®

Contributed by: PR Newswire

Tags

Accord-CHMP-IMULDOSA

More Like This

PR Newswire associated0

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®

CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)

European Commission approves Celltrion’s SteQeyma® (CT-P43), a biosimilar to Stelara® (ustekinumab), for the treatment of multiple chronic inflammatory diseases

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

PR Newswire associated0

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq®

PR Newswire associated0

Prestige Biopharma's Herceptin Biosimilar Tuznue® Receives Positive CHMP Opinion from the EMA